Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Atlas Salt Expands MOU with Sandvik Mining Supporting Great Atlantic Salt Project (click to learn more) Digital Health Meets AI -CSE: ALEN.U (click to learn more) New Gold Opportunities in the Cariboo Region (CSE:GCC) (OTC:GCCFF) (click to learn more) Why Herbal Dispatch (CSE:HERB) Is Getting Attention (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Azitra Inc AZTR

Healthcare Biotechnology
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:AZTR)

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

PR Newswire November 24, 2025

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

PR Newswire November 12, 2025

Azitra, Inc. Addresses False Report Regarding Sale of Securities

PR Newswire November 7, 2025

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

PR Newswire October 20, 2025

Azitra Receives Notice of Non-Compliance from NYSE American

PR Newswire October 3, 2025

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

PR Newswire September 4, 2025

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

PR Newswire August 27, 2025

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

PR Newswire August 11, 2025

Azitra, Inc. Announces Reverse Stock Split

PR Newswire August 11, 2025
View More News ››

Opinion & Analysis (NYSEAM:AZTR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:AZTR)

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway so good luck to all of you
coolfooldumbguy - August 22, 2025

AZTRA: Pioneering Precision Dermatology with Engineered Micr

http://beyondspx.com/2024/08/01/aztra-pioneering-precision-dermatology-with-engineered-microbes/
MikeTester - August 2, 2024
View more Bullboard ››

Blue Sky Uranium Corp.

Blue Sky Uranium Corp.

Blue Sky Uranium Corp., a junior uranium exploration company, engages in the acquisition, exploration, and evaluation of ...
View More »

Podcasts